Literature DB >> 35400199

In a Pinch: Cefiderocol for CRAB Infections.

Sara M Karaba1, Elizabeth B Hirsch2, Emily L Heil3.   

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. (https://doi.org/10.1128/aac.02142-21) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections treated with cefiderocol-containing versus colistin-containing regimens. Patients who received cefiderocol-containing regimens had lower 30-day mortality, though there are several limitations raised here, which make interpretation and applicability difficult.

Entities:  

Keywords:  Acinetobacter; CRAB; cefiderocol

Mesh：

Substances：

Year:  2022        PMID： 35400199      PMCID： PMC9112870          DOI： 10.1128/aac.00065-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  16 in total

1.  Cefiderocol: the Trojan horse has arrived but will Troy fall?

Authors:  Emily L Heil; Pranita D Tamma
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 25.071

Review 2.  Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.

Authors:  Jiating Liu; Yunfeng Shu; Feilong Zhu; Bimin Feng; Zhengjie Zhang; Liang Liu; Guojun Wang
Journal:  J Glob Antimicrob Resist       Date:  2020-09-02       Impact factor: 4.035

3.  Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy.

Authors:  Aryun Kim; Amy Kutschke; David E Ehmann; Sara A Patey; Jared L Crandon; Elise Gorseth; Alita A Miller; Robert E McLaughlin; Christina M Blinn; April Chen; Asha S Nayar; Brian Dangel; Andy S Tsai; Michael T Rooney; Kerry E Murphy-Benenato; Ann E Eakin; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

Review 4.  Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.

Authors:  Pranita D Tamma; Samuel L Aitken; Robert A Bonomo; Amy J Mathers; David van Duin; Cornelius J Clancy
Journal:  Clin Infect Dis       Date:  2022-07-06       Impact factor: 20.999

5.  Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa.

Authors:  Andrew P Tomaras; Jared L Crandon; Craig J McPherson; Mary Anne Banevicius; Steven M Finegan; Rebecca L Irvine; Matthew F Brown; John P O'Donnell; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

6.  Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  Alex P Betrosian; Frantzeska Frantzeskaki; Anna Xanthaki; Emmanuel E Douzinas
Journal:  J Infect       Date:  2008-05-23       Impact factor: 6.072

7.  Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Richard G Wunderink; Yuko Matsunaga; Mari Ariyasu; Philippe Clevenbergh; Roger Echols; Keith S Kaye; Marin Kollef; Anju Menon; Jason M Pogue; Andrew F Shorr; Jean-Francois Timsit; Markus Zeitlinger; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 25.071

Review 8.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

9.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421

Review 10.  Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?

Authors:  J Nicholas O'Donnell; Vibert Putra; Thomas P Lodise
Journal:  Pharmacotherapy       Date:  2021-07-22       Impact factor: 4.705
View more
  1 in total

1.  Reply to Epling and Powers, "Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients".

Authors:  Marco Falcone; Giusy Tiseo
Journal:  Antimicrob Agents Chemother       Date:  2022-07-18       Impact factor: 5.938
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.